Cumberland Pharmaceuticals Inc. (CPIX) Bundle
Ever wondered how a pharmaceutical company navigates the complexities of bringing specialized treatments to market?
Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. With $38 million in net revenues for the full year 2024, and a recent 11.6% increase in fourth-quarter revenue, Cumberland is making strides in the pharmaceutical industry, but how does it all work? Keep reading to find out more about Cumberland Pharmaceuticals' history, ownership, mission, operational model, and revenue streams.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) has a market capitalization of $56.71 million [as of April 15, 2025], but how does this specialty pharmaceutical company operate and generate revenue in the competitive healthcare market?
Cumberland Pharmaceuticals Inc. (CPIX) History
Cumberland Pharmaceuticals Inc. Founding Timeline
Year established
The company was founded in 1999.
Original location
The company is headquartered in Nashville, Tennessee.
Founding team members
Cumberland Pharmaceuticals was founded by A.J. Kazimi who serves as the current Chief Executive Officer.
Initial capital/funding
Information regarding the initial capital or funding for Cumberland Pharmaceuticals' founding is not readily available in the provided search results.
Cumberland Pharmaceuticals Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2003 | FDA Approval of Acetadote® | Acetadote® (acetylcysteine) receives FDA approval for the treatment of acetaminophen overdose. This marked Cumberland's entry into the pharmaceutical market with a critical care product. |
| 2004 | Acquisition of Kristalose® | Cumberland acquired Kristalose® (lactulose) for oral solution, expanding its product portfolio into gastroenterology. |
| 2006 | 上市 | Cumberland Pharmaceuticals went public and began trading on the NASDAQ stock exchange under the ticker symbol 'CPIX'. |
| 2011 | FDA Approval of Caldolor® | Caldolor® (ibuprofen) receives FDA approval for intravenous use as an antipyretic and analgesic. This approval strengthened Cumberland's presence in the hospital acute care market. |
| 2013 | Acquisition of Ofev® U.S. Rights | Cumberland acquired the U.S. rights to Ofev® (nintedanib) from Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF). |
Cumberland Pharmaceuticals Inc. Transformative Moments
- Strategic Acquisitions: Cumberland's growth strategy has heavily relied on acquiring established products like Kristalose® and Caldolor®, which diversified its portfolio and revenue streams.
- Focus on Hospital Acute Care: The company has strategically focused on developing and marketing products for the hospital acute care setting, demonstrated by the success of drugs like Acetadote® and Caldolor®.
- Navigating Regulatory and Legal Challenges: Cumberland has faced its share of regulatory and legal hurdles, including patent litigation and FDA approval processes, which have tested its resilience and strategic decision-making.
- Market Expansion and Partnerships: Expanding its market reach through strategic partnerships and distribution agreements has been crucial for penetrating new markets and maximizing product lifecycle.
To gain more insights into the company's financial stability, read this comprehensive analysis: Breaking Down Cumberland Pharmaceuticals Inc. (CPIX) Financial Health: Key Insights for Investors
Cumberland Pharmaceuticals Inc. (CPIX) Ownership Structure
Cumberland Pharmaceuticals operates with a mixed ownership structure, featuring a combination of institutional, retail, and insider holdings that influence its corporate governance and strategic direction.
Cumberland Pharmaceuticals Inc.'s Current Status
Cumberland Pharmaceuticals Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange. Investors can trade CPIX shares, allowing for broader ownership and market valuation of the company.
Cumberland Pharmaceuticals Inc.'s Ownership Breakdown
The ownership of Cumberland Pharmaceuticals is distributed among various types of shareholders. The following table provides a detailed breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 57.48% | Includes investment firms, mutual funds, and pension funds. |
| Individual Investors | 38.92% | Represents holdings by individual retail investors. |
| Insiders | 3.60% | Shares held by company executives and board members. |
Cumberland Pharmaceuticals Inc.'s Leadership
The leadership team at Cumberland Pharmaceuticals is responsible for the strategic direction and operational management of the company. Key members include:
- A.J. Messina: Currently serves as the Chief Executive Officer.
- John Hamm: Holds the position of Chief Financial Officer.
These individuals, along with other members of the executive team, guide Cumberland Pharmaceuticals in its mission to develop and commercialize pharmaceutical products.
To gain more insights into the dynamics of investment in Cumberland Pharmaceuticals, explore this resource: Exploring Cumberland Pharmaceuticals Inc. (CPIX) Investor Profile: Who’s Buying and Why?
Cumberland Pharmaceuticals Inc. (CPIX) Mission and Values
Cumberland Pharmaceuticals' mission is to acquire, develop, and commercialize brands for hospital acute care and gastroenterology. The company is committed to providing quality products that address unmet medical needs.
Cumberland Pharmaceuticals Inc.'s Core Purpose
Official mission statement
Cumberland Pharmaceuticals' mission statement is: 'To acquire, develop, and commercialize pharmaceutical products that improve quality of care and address unmet medical needs.'
Vision statement
While a specific vision statement is not formally declared, insights into Cumberland Pharmaceuticals' long-term aspirations can be gathered from their strategic decisions and corporate activities:
- Strategic Acquisitions and Development: Cumberland focuses on acquiring and developing pharmaceutical products that cater to specific medical needs, particularly in hospital acute care and gastroenterology.
- Market Expansion: Cumberland aims to broaden the market reach of its established products while introducing new and innovative treatments.
- Commitment to Quality: Cumberland prioritizes enhancing the quality of patient care through its pharmaceutical offerings.
Company slogan/tagline
Cumberland Pharmaceuticals does not have a widely publicized official slogan or tagline. However, their commitment to addressing unmet medical needs and improving patient care serves as an unofficial motto, reflecting their core values and goals.
To gain a deeper understanding of the company's financial performance, see Breaking Down Cumberland Pharmaceuticals Inc. (CPIX) Financial Health: Key Insights for Investors.
Cumberland Pharmaceuticals Inc. (CPIX) How It Works
Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical company, focusing on the acquisition, development, and commercialization of branded prescription products, aiming to address unmet medical needs, primarily in hospital acute care and gastroenterology.
Cumberland Pharmaceuticals' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Acetadote | Treatment for acetaminophen (Tylenol) overdose | Intravenous formulation of acetylcysteine, a well-established antidote that helps to prevent liver damage following acetaminophen overdose. |
| Caldolor | Management of pain and fever in adults and children | Intravenous ibuprofen formulation that provides rapid pain relief and fever reduction, particularly useful in patients who cannot take oral medications. |
| Kristalose | Treatment of hepatic encephalopathy | A prescription laxative, which is a synthetic non-absorbable sugar used to reduce ammonia levels in the body, thereby improving mental function in patients with liver disease. |
| Ofev (partnered with Boehringer Ingelheim) | Treatment of idiopathic pulmonary fibrosis (IPF) and other lung diseases | A kinase inhibitor that targets multiple growth factor receptors, helping to slow the progression of IPF and other fibrosing interstitial lung diseases. |
| Vaprisol | Treatment of hyponatremia (low sodium levels) in hospitalized patients | An intravenous vasopressin receptor antagonist that helps to increase serum sodium levels in patients with hyponatremia. |
| Boxaban | Management of post-operative pain | Oral ibuprofen approved for relief of postoperative pain. |
Cumberland Pharmaceuticals' Operational Framework
Cumberland Pharmaceuticals focuses on several key operational areas to create value:
- Product Acquisition and Development: Cumberland identifies and acquires promising pharmaceutical products or develops its own, focusing on areas with unmet medical needs.
- Manufacturing and Supply Chain: The company works with contract manufacturers to produce its products, ensuring a reliable supply chain and adherence to quality standards.
- Sales and Marketing: Cumberland employs a targeted sales force to promote its products to hospitals, physicians, and other healthcare providers. Marketing efforts emphasize the unique benefits and clinical data supporting the use of their products.
- Regulatory Compliance: Cumberland ensures that all products meet the requirements of regulatory bodies such as the FDA, maintaining high standards of safety and efficacy.
Cumberland Pharmaceuticals' Strategic Advantages
Cumberland Pharmaceuticals has several strategic advantages that enable its success:
- Specialty Focus: By concentrating on specific therapeutic areas like hospital acute care and gastroenterology, Cumberland develops deep expertise and targeted product offerings.
- Established Products: Many of Cumberland's products, like Acetadote, have a well-established reputation and clinical history, providing a competitive advantage.
- Strategic Partnerships: Collaborations with other pharmaceutical companies, such as the partnership with Boehringer Ingelheim for Ofev, expand Cumberland's market reach and product portfolio.
- Intellectual Property: Patents and other forms of intellectual property protection help to maintain market exclusivity for key products.
More information about the company can be found here: Mission Statement, Vision, & Core Values of Cumberland Pharmaceuticals Inc. (CPIX).
Cumberland Pharmaceuticals Inc. (CPIX) How It Makes Money
Cumberland Pharmaceuticals Inc. primarily generates revenue through the sale of its branded pharmaceutical products, which are distributed across various therapeutic areas.
Cumberland Pharmaceuticals Inc.'s Revenue Breakdown
Cumberland Pharmaceuticals focuses on the acquisition, development, and commercialization of pharmaceutical products. Their revenue streams are primarily derived from the sales of these products within the U.S. market.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Proprietary Products (e.g., Vibativ, Caldolor, Ofirmev) | > 90% | Stable to Increasing |
| Other Contract Manufacturing and Royalties | < 10% | Varies |
Cumberland Pharmaceuticals Inc.'s Business Economics
Cumberland Pharmaceuticals operates under a business model centered on developing, acquiring, and commercializing niche pharmaceutical products. The company's profitability is significantly influenced by its pricing strategies, cost management, and the competitive landscape for its key products.
- Pricing Power: Cumberland sets prices based on the clinical value and market demand for its products.
- Cost Efficiency: Efficient manufacturing and supply chain management are crucial for maintaining profitability.
- Market Dynamics: Competition from generics and alternative treatments can impact pricing and sales volumes.
To delve deeper into the profiles of investors who are engaging with companies like Cumberland Pharmaceuticals, you might find this resource insightful: Exploring Cumberland Pharmaceuticals Inc. (CPIX) Investor Profile: Who’s Buying and Why?
Cumberland Pharmaceuticals Inc.'s Financial Performance
Cumberland Pharmaceuticals' financial performance can be assessed through several key metrics that reflect its operational efficiency and profitability.
- Revenue Trends: Monitoring quarterly and annual revenue growth indicates the company's ability to expand sales of its products.
- Gross Margin: Analyzing gross margin helps evaluate the profitability of its products after accounting for the cost of goods sold.
- Operating Expenses: Tracking operating expenses as a percentage of revenue provides insights into the company's cost management strategies.
- Net Income: Reviewing net income and earnings per share (EPS) offers a comprehensive view of overall profitability.
- Cash Flow: Assessing cash flow from operations is vital for understanding the company's ability to generate cash from its core business activities.
These metrics provide a snapshot of Cumberland Pharmaceuticals' financial health and its capacity to sustain and grow its operations.
Cumberland Pharmaceuticals Inc. (CPIX) Market Position & Future Outlook
Cumberland Pharmaceuticals faces a competitive market landscape, with its future outlook dependent on strategic execution and navigating industry challenges. To gain more insights into the investors interested in CPIX, check out this profile: Exploring Cumberland Pharmaceuticals Inc. (CPIX) Investor Profile: Who’s Buying and Why?
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | N/A | Specialized product portfolio focused on hospital acute care and gastroenterology. |
| Mallinckrodt Pharmaceuticals | N/A | Established presence in specialty pharmaceuticals and generic products. |
| Bausch Health Companies Inc. | N/A | Diversified portfolio across various therapeutic areas including eye health, gastroenterology, and dermatology. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding the market reach of current products through strategic partnerships and distribution agreements. | Intense competition from generic drug manufacturers, leading to pricing pressure. |
| Acquiring or licensing new products to diversify the portfolio and address unmet medical needs. | Regulatory hurdles and potential delays in obtaining approvals for new drugs. |
| Capitalizing on the growing demand for specialized hospital acute care products. | Product liability claims and associated legal expenses. |
Industry Position
Cumberland Pharmaceuticals operates within the competitive pharmaceutical industry, focusing on niche markets. Key aspects of its industry positioning include:
- Niche Focus: Concentrating on specialized products for hospital acute care and gastroenterology allows Cumberland to address specific medical needs and potentially achieve higher margins.
- Product Portfolio: The company's portfolio includes established brands like Acetadote and Caldolor, providing a stable revenue base.
- Market Dynamics: The pharmaceutical industry is subject to continuous changes, including regulatory updates, technological advancements, and evolving patient needs.
Cumberland Pharmaceuticals Inc. (CPIX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.